XNASMGRX
Market cap5mUSD
Dec 26, Last price
2.62USD
1D
3.97%
1Q
992.12%
IPO
-14.10%
Name
Mangoceuticals Inc
Chart & Performance
P/E
—
P/S
6.87
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
731k
+8,083.16%
Net income
-9m
L+361.07%
CFO
-7m
L+419.66%
Profile
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | |||
Revenues | 731 8,083.16% | 9 | |
Cost of revenue | 8,850 | 2,353 | 18 |
Unusual Expense (Income) | |||
NOPBT | (8,118) | (2,344) | (18) |
NOPBT Margin | |||
Operating Taxes | (225) | (70) | |
Tax Rate | |||
NOPAT | (8,118) | (2,120) | 53 |
Net income | (9,212) 361.07% | (1,998) 11,187.81% | (18) |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 6,200 | 2,000 | 800 |
BB yield | -1,568.02% | ||
| Debt | |||
Debt current | 127 | 224 | 39 |
Long-term debt | 194 | 314 | |
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | (418) | (145) | 17 |
| Cash flow | |||
Cash from operating activities | (6,997) | (1,347) | (18) |
CAPEX | (4) | (43) | |
Cash from investing activities | (4) | (43) | |
Cash from financing activities | 7,057 | 2,050 | 40 |
FCF | (8,044) | (2,412) | |
| Balance | |||
Cash | 739 | 683 | 23 |
Long term investments | |||
Excess cash | 702 | 682 | 23 |
Stockholders' equity | (11,226) | (2,014) | (17) |
Invested Capital | 12,193 | 2,979 | 39 |
ROIC | 133.23% | ||
ROCE | |||
| EV | |||
Common stock shares outstanding | 1,428 | 17,315 | 17,315 |
Price | 0.28 | ||
Market cap | 395 | ||
EV | (23) | ||
EBITDA | (8,094) | (2,341) | (18) |
EV/EBITDA | 0.00 | ||
Interest | 6 | 181 | |
Interest/NOPBT | |||